BR112020020246A8 - Inibidores de cinase axl e uso dos mesmos - Google Patents
Inibidores de cinase axl e uso dos mesmosInfo
- Publication number
- BR112020020246A8 BR112020020246A8 BR112020020246A BR112020020246A BR112020020246A8 BR 112020020246 A8 BR112020020246 A8 BR 112020020246A8 BR 112020020246 A BR112020020246 A BR 112020020246A BR 112020020246 A BR112020020246 A BR 112020020246A BR 112020020246 A8 BR112020020246 A8 BR 112020020246A8
- Authority
- BR
- Brazil
- Prior art keywords
- kinase inhibitors
- axl kinase
- crystalline forms
- tartrate salts
- axl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/255—Tartaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Abstract
INIBIDORES DE CINASE AXL E USO DOS MESMOS . A presente invenção refere-se a sais de tartrato do composto de estrutura (I), formas cristalinas dos mesmos e aplicações terapêuticas dos mesmos para tratamento de tumores sólidos (por exemplo, tumor sólido avançado) ou cânceres hematopoiéticos. São também providos aqui métodos para síntese dos sais de tartrato e das formas cristalinas dos mesmos.
Applications Claiming Priority (21)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862653394P | 2018-04-05 | 2018-04-05 | |
US62/653,394 | 2018-04-05 | ||
US201862663146P | 2018-04-26 | 2018-04-26 | |
US62/663,146 | 2018-04-26 | ||
US201862678980P | 2018-05-31 | 2018-05-31 | |
US62/678,980 | 2018-05-31 | ||
US201862688161P | 2018-06-21 | 2018-06-21 | |
US62/688,161 | 2018-06-21 | ||
US201862695609P | 2018-07-09 | 2018-07-09 | |
US62/695,609 | 2018-07-09 | ||
US201862698638P | 2018-07-16 | 2018-07-16 | |
US62/698,638 | 2018-07-16 | ||
US201862760882P | 2018-11-13 | 2018-11-13 | |
US62/760,882 | 2018-11-13 | ||
US201862767475P | 2018-11-14 | 2018-11-14 | |
US62/767,475 | 2018-11-14 | ||
US201862778856P | 2018-12-12 | 2018-12-12 | |
US62/778,856 | 2018-12-12 | ||
US201962813705P | 2019-03-04 | 2019-03-04 | |
US62/813,705 | 2019-03-04 | ||
PCT/US2019/026094 WO2019195753A1 (en) | 2018-04-05 | 2019-04-05 | Axl kinase inhibitors and use of the same |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112020020246A2 BR112020020246A2 (pt) | 2021-01-12 |
BR112020020246A8 true BR112020020246A8 (pt) | 2022-10-18 |
Family
ID=68101236
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112020020246A BR112020020246A8 (pt) | 2018-04-05 | 2019-04-05 | Inibidores de cinase axl e uso dos mesmos |
Country Status (13)
Country | Link |
---|---|
US (3) | US11013741B1 (pt) |
EP (1) | EP3773591A4 (pt) |
JP (1) | JP2021524835A (pt) |
KR (1) | KR20210003780A (pt) |
CN (1) | CN112533602A (pt) |
AU (1) | AU2019247498A1 (pt) |
BR (1) | BR112020020246A8 (pt) |
CA (1) | CA3096984A1 (pt) |
IL (1) | IL277600A (pt) |
MX (1) | MX2020010437A (pt) |
PH (1) | PH12020551853A1 (pt) |
SG (1) | SG11202009443RA (pt) |
WO (1) | WO2019195753A1 (pt) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108997225A (zh) | 2013-03-14 | 2018-12-14 | 特雷罗药物股份有限公司 | Jak2和alk2抑制剂及其使用方法 |
US11013741B1 (en) | 2018-04-05 | 2021-05-25 | Sumitomo Dainippon Pharma Oncology, Inc. | AXL kinase inhibitors and use of the same |
WO2020023910A1 (en) | 2018-07-26 | 2020-01-30 | Tolero Pharmaceuticals, Inc. | Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same |
JP2022551439A (ja) * | 2019-10-04 | 2022-12-09 | スミトモ ファーマ オンコロジー, インコーポレイテッド | Axl阻害薬製剤 |
CA3184151A1 (en) * | 2020-06-29 | 2022-01-06 | Chris Murphy | Probenecid compounds for the treatment of inflammasome-mediated lung disease |
MX2023000810A (es) * | 2020-07-19 | 2023-05-19 | Aravive Inc | Metodos de diagnostico para el cancer utilizando receptores señuelo axl. |
WO2023134582A1 (zh) * | 2022-01-14 | 2023-07-20 | 上海立森印迹医药技术有限公司 | 一种嘧啶-2,4-二胺衍生物及其制备方法和用途 |
Family Cites Families (128)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
PT821671E (pt) | 1995-04-20 | 2001-04-30 | Pfizer | Derivados do acido arilsulfonil hidroxamico como inibidores de mmp e tnf |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
DE69624081T2 (de) | 1995-12-20 | 2003-06-12 | Hoffmann La Roche | Matrix-metalloprotease Inhibitoren |
EP0818442A3 (en) | 1996-07-12 | 1998-12-30 | Pfizer Inc. | Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor |
WO1998003516A1 (en) | 1996-07-18 | 1998-01-29 | Pfizer Inc. | Phosphinate based inhibitors of matrix metalloproteases |
IL128189A0 (en) | 1996-08-23 | 1999-11-30 | Pfizer | Arylsulfonylamino hydroxamic acid derivatives |
AU719392B2 (en) | 1996-10-01 | 2000-05-11 | Kyowa Hakko Kirin Co., Ltd. | Nitrogen-containing heterocyclic compounds |
EP0950059B1 (en) | 1997-01-06 | 2004-08-04 | Pfizer Inc. | Cyclic sulfone derivatives |
ES2202796T3 (es) | 1997-02-03 | 2004-04-01 | Pfizer Products Inc. | Derivados de acidos arilsulfonilaminohidroxamicos. |
EP0966438A1 (en) | 1997-02-07 | 1999-12-29 | Pfizer Inc. | N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases |
JP3710489B2 (ja) | 1997-02-11 | 2005-10-26 | ファイザー・インク | アリールスルホニルヒドロキサム酸誘導体 |
UA61963C2 (en) | 1997-08-08 | 2003-12-15 | Pfizer Prod Inc | Aryloxysulfonylaminohydroxamic acid derivatives |
GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
JP4462654B2 (ja) | 1998-03-26 | 2010-05-12 | ソニー株式会社 | 映像素材選択装置及び映像素材選択方法 |
PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
US6114361A (en) | 1998-11-05 | 2000-09-05 | Pfizer Inc. | 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives |
WO2000035436A2 (en) | 1998-12-16 | 2000-06-22 | Warner-Lambert Company | Treatment of arthritis with mek inhibitors |
US6511993B1 (en) | 1999-06-03 | 2003-01-28 | Kevin Neil Dack | Metalloprotease inhibitors |
IN191496B (pt) * | 1999-07-30 | 2003-12-06 | Ranbaxy Lab Ltd | |
EP1081137A1 (en) | 1999-08-12 | 2001-03-07 | Pfizer Products Inc. | Selective inhibitors of aggrecanase in osteoarthritis treatment |
GB9924862D0 (en) | 1999-10-20 | 1999-12-22 | Celltech Therapeutics Ltd | Chemical compounds |
CN1429222A (zh) | 2000-02-17 | 2003-07-09 | 安姆根有限公司 | 激酶抑制剂 |
AU5889701A (en) | 2000-06-05 | 2001-12-17 | Dong A Pharm Co Ltd | Novel oxazolidinone derivatives and a process for the preparation thereof |
PL203387B1 (pl) | 2000-07-19 | 2009-09-30 | Warner Lambert Co | Utlenione estry kwasu 4-jodofenyloaminobenzhydroksamowego |
EP1315715B1 (en) | 2000-08-18 | 2008-07-23 | Millennium Pharmaceuticals, Inc. | Quinazoline derivatives as kinase inhibitors |
US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
US6939874B2 (en) | 2001-08-22 | 2005-09-06 | Amgen Inc. | Substituted pyrimidinyl derivatives and methods of use |
RU2343148C2 (ru) | 2002-02-01 | 2009-01-10 | Райджел Фармасьютикалз, Инк | Соединения 2,4-пиримидиндиаминов и их применение |
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
NZ535101A (en) | 2002-03-08 | 2007-07-27 | Eisai Co Ltd | Macrocyclic compounds useful as pharmaceuticals |
AR038971A1 (es) | 2002-03-13 | 2005-02-02 | Array Biopharma Inc | Derivados de bencimidazol n3 alquilado como inhibidores de mek |
GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
AU2003231231A1 (en) | 2002-05-06 | 2003-11-11 | Bayer Pharmaceuticals Corporation | Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders |
JP4608852B2 (ja) | 2002-10-15 | 2011-01-12 | チッソ株式会社 | 液晶性ビニルケトン誘導体およびその重合体 |
JP2006151810A (ja) | 2002-12-26 | 2006-06-15 | Daiichi Asubio Pharma Co Ltd | ジヒドロチエノキノリン誘導体及びそれを含む細胞接着阻害剤 |
ES2325440T3 (es) | 2003-02-20 | 2009-09-04 | Smithkline Beecham Corporation | Compuestos de pirimidina. |
GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
DK1660458T3 (da) | 2003-08-15 | 2012-05-07 | Irm Llc | 2, 4-pyrimidindiaminer egnede i behandling af neoplastiske sygdomme, in-flammatoriske lidelser og lidelser i immunsystemet. |
JP2007505858A (ja) | 2003-09-18 | 2007-03-15 | ノバルティス アクチエンゲゼルシャフト | 増殖性障害の処置に有用な2,4−ジ(フェニルアミノ)ピリミジン |
ATE437872T1 (de) | 2003-10-14 | 2009-08-15 | Univ Arizona | Proteinkinaseinhibitoren |
WO2005082892A2 (en) | 2004-02-17 | 2005-09-09 | Dr. Reddy's Laboratories Ltd. | Triazole compounds as antibacterial agents and pharmaceutical compositions containing them |
JP2007532558A (ja) | 2004-04-09 | 2007-11-15 | メルク エンド カムパニー インコーポレーテッド | Akt活性の阻害剤 |
TW200633990A (en) | 2004-11-18 | 2006-10-01 | Takeda Pharmaceuticals Co | Amide compound |
CA2604284A1 (en) | 2005-04-28 | 2006-11-02 | Supergen, Inc. | Protein kinase inhibitors |
WO2007027238A2 (en) | 2005-05-03 | 2007-03-08 | Rigel Pharmaceuticals, Inc. | Jak kinase inhibitors and their uses |
WO2006124874A2 (en) | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Inhibitors of b-raf kinase |
US20070032514A1 (en) | 2005-07-01 | 2007-02-08 | Zahn Stephan K | 2,4-diamino-pyrimidines as aurora inhibitors |
WO2007014011A2 (en) | 2005-07-21 | 2007-02-01 | Ardea Biosciences, Inc. | N-(arylamino)-sulfonamide inhibitors of mek |
WO2007020888A1 (ja) | 2005-08-12 | 2007-02-22 | Takeda Pharmaceutical Company Limited | 脳・神経細胞保護剤および睡眠障害治療薬 |
US8133900B2 (en) | 2005-11-01 | 2012-03-13 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
US8604042B2 (en) | 2005-11-01 | 2013-12-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
KR101467723B1 (ko) | 2005-11-01 | 2014-12-03 | 탈자진 인코포레이티드 | 키나제의 비-아릴 메타-피리미딘 억제제 |
AU2006336506B2 (en) | 2006-01-13 | 2012-06-28 | Pharmacyclics Llc | Inhibitors of tyrosine kinases and uses thereof |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
KR20080110998A (ko) | 2006-01-30 | 2008-12-22 | 엑셀리시스, 인코포레이티드 | Jak2 조절자로서 4아릴2아미노피리미딘 또는 4아릴2아미노알킬피리미딘 및 이들을 포함하는 약제학적 조성물 |
JP2009528295A (ja) | 2006-02-24 | 2009-08-06 | ライジェル ファーマシューティカルズ, インコーポレイテッド | Jak経路の阻害のための組成物および方法 |
EP2054392A2 (en) | 2006-06-15 | 2009-05-06 | Boehringer Ingelheim International GmbH | 2-anilino-4-(heterocyclic)amino-pyrimidines as inhibitors of protein kinase c-alpha |
HUE028086T2 (en) | 2006-09-22 | 2016-11-28 | Pharmacyclics Llc | Bruton tyrosine kinase inhibitors |
US20080207632A1 (en) | 2006-10-31 | 2008-08-28 | Supergen, Inc. | Protein kinase inhibitors |
US8987233B2 (en) | 2006-11-03 | 2015-03-24 | Pharmacyclics, Inc. | Bruton's tyrosine kinase activity probe and method of using |
EA019966B1 (ru) | 2006-12-08 | 2014-07-30 | АйАрЭм ЭлЭлСи | Соединения и композиции в качестве ингибиторов протеинкиназы |
TW200902010A (en) | 2007-01-26 | 2009-01-16 | Smithkline Beecham Corp | Anthranilamide inhibitors of aurora kinase |
EP2114900B1 (en) | 2007-01-31 | 2018-10-10 | YM BioSciences Australia Pty Ltd | Thiopyrimidine-based compounds and uses thereof |
KR20090129434A (ko) | 2007-03-01 | 2009-12-16 | 수퍼젠, 인크. | 피리미딘-2,4-디아민 유도체 및 jak2 키나제 억제제로서의 이의 용도 |
CN101657431A (zh) | 2007-03-01 | 2010-02-24 | 休普基因公司 | 嘧啶-2,4-二胺衍生物及其作为jak2激酶抑制剂的用途 |
WO2008118823A2 (en) | 2007-03-26 | 2008-10-02 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
US20120101114A1 (en) | 2007-03-28 | 2012-04-26 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
CA3001152A1 (en) | 2007-03-28 | 2008-10-09 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
WO2008124085A2 (en) | 2007-04-03 | 2008-10-16 | Exelixis, Inc. | Methods of using combinations of mek and jak-2 inhibitors |
CA2682733A1 (en) | 2007-04-13 | 2008-10-23 | Supergen, Inc. | Axl kinase inhibitors |
CA2686378C (en) | 2007-05-04 | 2012-07-24 | Irm Llc | Pyrimidine derivatives and compositions as c-kit and pdgfr kinase inhibitors |
WO2009010794A1 (en) | 2007-07-19 | 2009-01-22 | Astrazeneca Ab | 2,4-diamino-pyrimidine derivatives |
MX338504B (es) | 2007-09-12 | 2016-04-20 | Genentech Inc | Combinaciones de compuestos inhibidores de fosfoinosituro 3-cinasa y agentes quimioterapeuticos, y metodos de uso. |
JP5348725B2 (ja) | 2007-10-25 | 2013-11-20 | ジェネンテック, インコーポレイテッド | チエノピリミジン化合物の製造方法 |
CA2710118A1 (en) | 2007-12-20 | 2009-07-02 | Cellzome Limited | Sulfamides as zap-70 inhibitors |
US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
RU2536584C2 (ru) | 2008-06-27 | 2014-12-27 | Авила Терапьютикс, Инк. | Гетероарильные соединения и их применение |
WO2010009342A2 (en) | 2008-07-16 | 2010-01-21 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors |
US20100029675A1 (en) | 2008-07-25 | 2010-02-04 | Hwang Soo-In | Pyrimidine-2, 4-diamine JAK2 Kinase inhibiting anti-inflammation use |
WO2010017122A2 (en) | 2008-08-05 | 2010-02-11 | Targegen Inc. | Methods of treating thalassemia |
PT2389372E (pt) | 2009-01-23 | 2016-01-07 | Rigel Pharmaceuticals Inc | Composições e métodos para a inibição da via jak |
WO2010090764A1 (en) | 2009-02-09 | 2010-08-12 | Supergen, Inc. | Pyrrolopyrimidinyl axl kinase inhibitors |
WO2010118986A1 (en) | 2009-04-14 | 2010-10-21 | Cellzome Limited | Fluoro substituted pyrimidine compounds as jak3 inhibitors |
WO2011031896A2 (en) | 2009-09-09 | 2011-03-17 | Avila Therapeutics, Inc. | Pi3 kinase inhibitors and uses thereof |
US7718662B1 (en) | 2009-10-12 | 2010-05-18 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase |
AU2010306927A1 (en) | 2009-10-12 | 2012-05-31 | Myrexis, Inc. | Amino - pyrimidine compounds as inhibitors of TBKL and/or IKK epsilon |
AU2011211306B2 (en) | 2010-01-29 | 2016-07-07 | Otsuka Pharmaceutical Co., Ltd. | Di - substituted pyridine derivatives as anticancers |
CA2800913C (en) | 2010-06-03 | 2019-07-23 | Pharmacyclics, Inc. | The use of inhibitors of bruton's tyrosine kinase (btk) |
CA2794731C (en) | 2010-06-18 | 2019-03-19 | Genentech, Inc. | Anti-axl antibodies and methods of use |
WO2012135641A2 (en) | 2011-03-30 | 2012-10-04 | H. Lee Moffitt Cancer Center And Research Institute | Aurora kinase inhibitors and methods of making and using thereof |
EP2693881B1 (en) * | 2011-04-01 | 2019-09-04 | University of Utah Research Foundation | Substituted n-phenylpyrimidin-2-amine analogs as inhibitors of the axl kinase |
WO2012135801A1 (en) | 2011-04-01 | 2012-10-04 | University Of Utah Research Foundation | Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors |
WO2013010136A2 (en) | 2011-07-13 | 2013-01-17 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
JP6506555B2 (ja) | 2011-10-19 | 2019-04-24 | ファーマサイクリックス エルエルシー | ブルトン型チロシンキナーゼ(Btk)阻害剤の使用 |
CN103087077B (zh) | 2011-11-03 | 2016-05-18 | 上海希迈医药科技有限公司 | 噻吩并嘧啶和呋喃并嘧啶类衍生物、其制备方法及其在医药上的应用 |
US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
US8501724B1 (en) | 2012-01-31 | 2013-08-06 | Pharmacyclics, Inc. | Purinone compounds as kinase inhibitors |
WO2013173518A1 (en) | 2012-05-16 | 2013-11-21 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
CN110354132A (zh) | 2012-06-04 | 2019-10-22 | 药品循环有限责任公司 | 布鲁顿酪氨酸激酶抑制剂的晶形 |
EP2877598A1 (en) | 2012-07-24 | 2015-06-03 | Pharmacyclics, Inc. | Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk) |
US8703981B2 (en) | 2012-08-03 | 2014-04-22 | Xerox Corporation | Lignosulfonate compounds for solid ink applications |
ES2618007T3 (es) | 2012-08-06 | 2017-06-20 | Acea Biosciences, Inc. | Nuevos compuestos de pirrolopirimidina como inhibidores de proteína cinasas |
KR101446742B1 (ko) | 2012-08-10 | 2014-10-01 | 한국화학연구원 | N2,n4-비스(4-(피페라진-1-일)페닐)피리미딘-2,4-디아민 유도체 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
BR112015005894B1 (pt) * | 2012-09-18 | 2022-03-29 | Auspex Pharmaceuticals, Inc | Composto, composição farmacêutica, método para tratar um distúrbio mediado por vmat2 e formulação farmacêutica de liberação prolongada |
CA2886275A1 (en) | 2012-09-26 | 2014-04-03 | Mannkind Corporation | Multiple kinase pathway inhibitors |
BR112015011171A2 (pt) | 2012-11-15 | 2017-07-11 | Pharmacyclics Inc | compostos de pirrolopirimidina como inibidores da quinase |
ES2805359T3 (es) | 2013-02-08 | 2021-02-11 | Celgene Car Llc | Inhibidores de ERK y sus usos |
WO2014130411A1 (en) | 2013-02-22 | 2014-08-28 | Emory University | Tgf-beta enhancing compositions for cartilage repair and methods related thereto |
US9708326B2 (en) | 2013-02-25 | 2017-07-18 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
CN108997225A (zh) | 2013-03-14 | 2018-12-14 | 特雷罗药物股份有限公司 | Jak2和alk2抑制剂及其使用方法 |
US20160022683A1 (en) | 2013-03-14 | 2016-01-28 | Pharmacyclics Llc | Combinations of bruton's tyrosine kinase inhibitors and cyp3a4 inhibitors |
JP6473133B2 (ja) | 2013-03-15 | 2019-02-20 | アラクセス ファーマ エルエルシー | Krasg12cの共有結合性阻害剤 |
WO2014143659A1 (en) | 2013-03-15 | 2014-09-18 | Araxes Pharma Llc | Irreversible covalent inhibitors of the gtpase k-ras g12c |
EP2983670A4 (en) | 2013-04-08 | 2017-03-08 | Pharmacyclics LLC | Ibrutinib combination therapy |
JP6458018B2 (ja) | 2013-07-02 | 2019-01-23 | ファーマサイクリックス エルエルシー | キナーゼ阻害剤としてのプリノン化合物 |
KR20160062103A (ko) | 2013-09-30 | 2016-06-01 | 파마싸이클릭스 엘엘씨 | 브루톤 티로신 키나제의 억제제 |
KR20160076519A (ko) | 2013-10-10 | 2016-06-30 | 아락세스 파마 엘엘씨 | Kras g12c 억제제 |
MX2016005925A (es) | 2013-11-05 | 2016-11-28 | Cognate Bioservices Inc | Combinaciones de inhibidores de punto de regulacion y terapeuticos para tratar el cancer. |
MX2017008430A (es) * | 2014-12-23 | 2018-03-23 | Cephalon Inc | Métodos para preparar derivados de 2,4-diaminopirimidina bíclica fusionada. |
JP6510075B2 (ja) | 2015-05-18 | 2019-05-08 | トレロ ファーマシューティカルズ, インコーポレイテッド | バイオアベイラビリティが高いアルボシジブプロドラッグ |
CN108495927A (zh) | 2015-11-23 | 2018-09-04 | 波士顿大学董事会 | 嵌合抗原受体相关的方法和组合物 |
US11013741B1 (en) | 2018-04-05 | 2021-05-25 | Sumitomo Dainippon Pharma Oncology, Inc. | AXL kinase inhibitors and use of the same |
-
2019
- 2019-04-05 US US16/376,452 patent/US11013741B1/en active Active
- 2019-04-05 WO PCT/US2019/026094 patent/WO2019195753A1/en active Search and Examination
- 2019-04-05 EP EP19780739.9A patent/EP3773591A4/en active Pending
- 2019-04-05 MX MX2020010437A patent/MX2020010437A/es unknown
- 2019-04-05 CN CN201980033174.9A patent/CN112533602A/zh active Pending
- 2019-04-05 JP JP2020523746A patent/JP2021524835A/ja active Pending
- 2019-04-05 SG SG11202009443RA patent/SG11202009443RA/en unknown
- 2019-04-05 CA CA3096984A patent/CA3096984A1/en active Pending
- 2019-04-05 AU AU2019247498A patent/AU2019247498A1/en active Pending
- 2019-04-05 BR BR112020020246A patent/BR112020020246A8/pt unknown
- 2019-04-05 KR KR1020207031834A patent/KR20210003780A/ko unknown
-
2020
- 2020-09-24 IL IL277600A patent/IL277600A/en unknown
- 2020-11-03 PH PH12020551853A patent/PH12020551853A1/en unknown
- 2020-11-09 US US17/092,521 patent/US11400091B2/en active Active
-
2022
- 2022-06-09 US US17/836,698 patent/US20230165857A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP3773591A4 (en) | 2021-12-22 |
CN112533602A (zh) | 2021-03-19 |
AU2019247498A1 (en) | 2020-11-26 |
US11400091B2 (en) | 2022-08-02 |
IL277600A (en) | 2020-11-30 |
SG11202009443RA (en) | 2020-10-29 |
WO2019195753A1 (en) | 2019-10-10 |
PH12020551853A1 (en) | 2021-07-19 |
KR20210003780A (ko) | 2021-01-12 |
US20210205304A1 (en) | 2021-07-08 |
CA3096984A1 (en) | 2019-10-10 |
US11013741B1 (en) | 2021-05-25 |
EP3773591A1 (en) | 2021-02-17 |
BR112020020246A2 (pt) | 2021-01-12 |
US20230165857A1 (en) | 2023-06-01 |
MX2020010437A (es) | 2021-01-29 |
JP2021524835A (ja) | 2021-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112020020246A8 (pt) | Inibidores de cinase axl e uso dos mesmos | |
BR112018070163A2 (pt) | compostos de aminopurina substituída, composições e métodos de tratamento | |
BR112019024525A2 (pt) | composto, sal farmaceuticamente aceitável e formulação farmacêutica de inibidores de kras c12c | |
CY1122611T1 (el) | Ενωσεις πυραζολοπυριμιδινης ως αναστολεις κινασης | |
CL2019002461A1 (es) | Arn terapéutico. | |
WO2018140831A3 (en) | Tumor targeting conjugates and methods of use thereof | |
ECSP22011692A (es) | Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2 | |
MX2018011792A (es) | Compuestos de pirrolotriazina como inhibidores de tyro3, axl y mer (tam). | |
EA201990187A1 (ru) | Антипролиферационные средства на основе пиримидина | |
EA202090497A1 (ru) | Соединения и композиции для лечения гематологических нарушений | |
EA201990189A1 (ru) | Синтез n-(гетероарил)пирроло[3,2-d]пиримидин-2-аминов | |
EA201790492A1 (ru) | СОЕДИНЕНИЯ, КОТОРЫЕ ИНГИБИРУЮТ БЕЛОК Mcl-1 | |
EP4303583A3 (en) | Methods of treating disorders using csf1r inhibitors cross-reference to related applications | |
EA201890730A1 (ru) | Производные пиразолопиримидина в качестве ингибиторов btk для лечения злокачественного новообразования | |
WO2016161410A3 (en) | Treatment of cancer using inhibitors of tgf-beta and pd-1 | |
CL2012003680A1 (es) | Compuestos derivados de (1,8) naftiridinas 2,4 diaril sustituidas inhibidores de quinasas; su procedimiento de obtencion; composicion farmaceutica; y su uso para el tratamiento y/o prevencion de cancer, tumor, tumores malignos, entre otros; kit farmaceutico. | |
CY1122364T1 (el) | Αναστολεις της ezh2 | |
EA201991622A1 (ru) | Комплексная терапия для лечения рака | |
BR112018068412A2 (pt) | composto, composição farmacêutica, método de tratamento de síndrome mielodisplásica e método para matar uma célula tumoral | |
EA202193015A1 (ru) | Ингибиторы cdk | |
BR112019024719A2 (pt) | Composições e métodos para resposta imunológica antitumor aprimorada | |
MX2022000310A (es) | Inhibidores de proteina bcl-2. | |
MX2019009356A (es) | Sulfinilpiridinas y su uso en el tratamiento del cancer. | |
UY36758A (es) | Inhibidores del potenciador del homólogo zeste 2 | |
BR112022012867A2 (pt) | Tratamento de câncer com inibidores de cdk12/13 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B25D | Requested change of name of applicant approved |
Owner name: SUMITOMO PHARMA ONCOLOGY, INC. (US) |